News for EyePoint Pharmaceuticals, Inc. (EYPT)

”“ Generated Record Quarterly and Full-Year Net Revenue of $181.9 Million and $631.4 Million ”“ ”“ Reported Quarterly Jornay PM® Net Revenue of $29

**media[552841]**

WATERTOWN, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. ( EYPT), a company committed to developing and commercializing innovative t

”“ Company presentation scheduled on Tuesday, March 4th at 9:10am ET ”“ ”“ EyePoint to provide enrollment update for ongoing DURAVYUâ„¢ Phase 3 pivotal pr

**media[542275]**

WATERTOWN, Mass., Feb. 17, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. ( EYPT), a company committed to developing and commercializing therapeutics

On December 31, 2024, RA CAPITAL MANAGEMENT, L.P. (Trades, Portfolio) executed a noteworthy transaction by acquiring 3,181,818 shares of EyePoint Pharmaceutical

EyePoint (EYPT) stock rose 10% after the company reported six-month results from a phase 2 study of its drug Duravyu in the treatment of diabetic macular edema. Read more here.

EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic macular edema or DME.

**media[532850]**

**media[532721]**

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last October, expects to report full topline results in the first quarter of 2025.

On December 31, 2024, Franklin Resources Inc., a prominent investment management firm, expanded its portfolio by acquiring an additional 125,519 shares of EyePo

**media[516696]**

WATERTOWN, Mass., Jan. 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. ( EYPT), a company committed to developing and commercializing therapeutics

”“ Enrollment in DURAVYU Phase 3 wet AMD clinical trials exceeding expectations with the LUGANO trial one-third enrolled and the LUCIA trial tracking ahead of

VEGFR2 (vascular endothelial growth factor receptor 2) antagonist is an antineoplastic agent that blocks the binding of natural VEGF ligands, which are...

Enthusiasm about artificial intelligence helped drive collective gains in global equities during the second quarter of 2024. Click here to read the full fund letter.

Loading... Loading... Shares of ASP Isotopes Inc. ASPI fell during Friday's session after the company announced pricing of a $30 million public offering of 12 ...